Intraperitoneal penetration of ciprofloxacin

Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams

The penetration of ciprofloxacin into the ascitic fluid of eight patients was studied. Serum and ascitic fluid samples were obtained before and at 1, 2, 3, 6, and 12 h following administration of a single oral dose of 750 mg. Peak levels (mean +/- standard deviation) were 4.0 +/- 0.7 micrograms/ml in serum and 2.6 +/- 0.6 micrograms/ml in ascitic fluid; the areas under the curve (0 to 12 h) were 29.1 +/- 6.5 micrograms.h/ml in serum and 20.7 +/- 5.0 micrograms.h/ml in ascitic fluid. The concentrations that were achieved are well above the MICs of ciprofloxacin for the members of the family Enterobacteriaceae that cause spontaneous bacterial peritonitis.

Penetration of ciprofloxacin into human peritoneal tissue following a single oral dose of 750 milligrams

The penetration of ciprofloxacin into the peritoneal tissue was studied in 10 patients after a single oral dose of 750 mg given 5.6 hours (mean) before elective laparotomy. The mean tissue level was 0.29 micrograms/ml (range, 0.082 to 0.96 micrograms/ml) while the mean concomitant serum level was 1.3 micrograms/g (range, 0.52 to 2.57 micrograms/g). The achieved concentrations are above the minimum inhibitory concentrations (MICs) of ciprofloxacin for most gram-negative bacteria commonly involved in intra-abdominal infections.

A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection

A prospective randomised study was undertaken in 80 patients to assess the combined regimen of ciprofloxacin with metronidazole against amoxicillin/clavulanic acid with metronidazole as treatment for established intra-abdominal infection. Treatment was for five days. Seventy-eight patients were clinically evaluable (38 patients on ciprofloxacin with metronidazole and 40 patients on amoxicillin/clavulanic acid with metronidazole). The overall clinical success rate in the treatment of intra-abdominal infections was 96% for the ciprofloxacin with metronidazole group, and 90% for the amoxicillin/clavulanic acid with metronidazole group. Over half of all patients were able to change from intravenous to oral antibiotic administration within the study period. One patient receiving ciprofloxacin with metronidazole developed pruritus near the injection site.

Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones

The third generation quinolones, ciprofloxacin, enoxacin, fleroxacin, norfloxacin, ofloxacin and pefloxacin are all quickly and quantitatively well (75-95% of an oral dose) absorbed upon oral administration. The maximum serum concentrations appear after 1-2 hours. The serum and urine concentrations after oral or intravenous ciprofloxacin are directly proportional with the doses and follow normal, dose-independent pharmacokinetics. Ciprofloxacin and norfloxacin reach the same serum levels after the same doses. Steady-state levels are indifferent from those after the first dose. In contrast, enoxacin, oflaxacin and pefloxacin do reach somewhat higher levels after chronic administration. Ciprofloxacin is eliminated by the kidneys (active tubular secretion which is blocked by probenecid) (60% after an intravenous administration), by metabolism and by the transintestinal route. Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin). Transintestinal elimination implies that the drug is eliminated by transport across the intestinal wall without significant biliary elimination (which is less than 1%). Penetration into tissues occurs readily. Concentrations in prostate secretion are high for ciprofloxacin and norfloxacin. Ciprofloxacin reaches high intracellular concentrations; within human neutrophils the levels reach 6 times the concentrations in the surrounding fluid. Concentrations in bile and tissues are in general comparable to those in serum. Cerebrospinal fluid (CSF) concentrations are low when meningi are normal, but 40-90% of the serum levels when the meninges are inflamed. Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions

Ciprofloxacin, considered a benchmark when comparing new fluoroquinolones, shares with these agents a common mechanism of action: inhibition of DNA gyrase. While ciprofloxacin demonstrated a fairly good activity against gram-positive bacteria, it is against gram-negative organisms that it proved to be more potent than other fluoroquinolones. It is the most active quinolone against Pseudomonas aeruginosa, with MIC90s on the order of 0.5 micrograms/ml. When given orally, ciprofloxacin exhibited 70% bioavailability and attained peak serum levels ranging between 1.5 and 2.9 micrograms/ml after a single 500-mg dose. Nineteen percent of an oral dose was excreted as metabolites in both urine and feces. In most cases, body fluids and tissue concentrations equaled or exceeded those in concurrent serum samples. In clinical trials, oral and intravenous ciprofloxacin yielded similar clinical and bacteriologic results compared to standard therapy in a wide array of systemic infections, including lower and upper urinary tract infections; gonococcal urethritis; skin, skin structure, and bone infections; and respiratory tract and gastrointestinal tract infections. Major benefits with the oral form of this quinolone are expected in chronic pyelonephritis and bone infections, and in pulmonary exacerbations in patients with cystic fibrosis. Emergence of ciprofloxacin-resistant microorganisms has been noted in clinical practice, primarily Pseudomonas aeruginosa and Staphylococcus aureus. The most frequent side effects are related to the gastrointestinal tract; but attention should be given to adverse central nervous system effects.

Ciprofloxacin

Ciprofloxacin is a new fluorinated quinolone antibiotic with high activity against a wide spectrum of gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas aeruginosa. Clinical trials using the oral preparation of ciprofloxacin have demonstrated its effectiveness in a wide variety of infections. In addition, extensive clinical trials with the intravenous preparation are underway. In vitro and in vivo studies with ciprofloxacin have reported the incidence of resistant organisms to be very low. In addition, the incidence of ciprofloxacin-related side effects throughout its clinical trials has been minimal. Most reports of side effects have been related to the gastrointestinal tract, such as nausea or vomiting. The incidence of adverse experiences in worldwide clinical trials has been reported to be approximately 6.4 percent.